| Name | Title | Contact Details |
|---|---|---|
Scott Radley |
Director Information Security | Profile |
Brad Wells |
Executive Director, Information Security | Profile |
Kandice Samuelson |
Senior Director, Information Technology | Profile |
BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime`s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime`s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX.
At Travere Therapeutics, our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. #InRareForLife
BrainScope is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Wolfe Laboratories is a Watertown, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DMC is leading the low cost sustainable transformation of multiple product markets.